Xolegel™ receives marketing approval in Canada

Journal of Drugs in Dermatology, May, 2007 by Marissa Heller

Barrier Therapeutics, Inc recently announced that it has received marketing approval for Xolegel in Canada. Xolegel (ketoconazole, topical gel, 2%) is approved for the treatment of seborrheic dermatitis in immunocompetent adults and children who are at least 12 years old.

Xolegel is approved for use once daily for 2 weeks and has been shown to be both safe and efficacious. The medication received US FDA approval in July 2006 and was launched in the US in November 2006. It is the only FDA-approved prescription gel formulation of ketoconazole. The product will likely be launched in Canada later this year.

Marissa Heller MD

New York University, Department of Dermatology

Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatological community. These features may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new products. In addition, we will infrom our readers about the latest drugs receiving FDA approval. We trust you will find this information beneficial to your practice and research.